| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
24,727 |
196,382 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,194,336 |
$28,520,846 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
20 |
73 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2015-12-07 |
5 |
GD |
$0.00 |
$0 |
D/D |
260 |
35,647 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-12-02 |
4 |
S |
$148.49 |
$62,960 |
D/D |
(424) |
1,310 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-12-01 |
4 |
S |
$145.96 |
$1,465,910 |
I/I |
(10,000) |
4,716 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2015-11-23 |
4 |
AS |
$145.13 |
$1,514,928 |
D/D |
(10,243) |
1,130,547 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2015-11-20 |
4 |
AS |
$144.12 |
$2,564,368 |
D/D |
(17,725) |
1,140,790 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2015-11-16 |
4 |
AS |
$134.03 |
$13,403 |
D/D |
(100) |
13,690 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2015-11-13 |
4 |
S |
$135.37 |
$382,737 |
D/D |
(2,821) |
19,146 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2015-11-10 |
4 |
AS |
$128.53 |
$321,325 |
D/D |
(2,500) |
289,355 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-11-10 |
4 |
S |
$128.96 |
$1,352,862 |
I/I |
(10,000) |
4,912 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2015-10-21 |
4 |
AS |
$125.00 |
$250,006 |
D/D |
(2,000) |
35,855 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2015-10-15 |
4 |
AS |
$131.86 |
$13,186 |
D/D |
(100) |
13,790 |
|
- |
|
| Cozadd Bruce C |
Chairman and CEO |
• • – |
2015-10-13 |
4 |
AS |
$131.50 |
$328,750 |
D/D |
(2,500) |
291,855 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-10-05 |
4 |
S |
$132.26 |
$1,337,860 |
I/I |
(10,000) |
5,108 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2015-09-25 |
4 |
AS |
$145.23 |
$14,523 |
D/D |
(100) |
13,890 |
|
- |
|
| Cozadd Bruce C |
Chairman and CEO |
• • – |
2015-09-08 |
4 |
AS |
$162.86 |
$407,679 |
D/D |
(2,500) |
294,355 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-09-01 |
4 |
S |
$164.50 |
$1,659,852 |
I/I |
(10,000) |
5,304 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2015-08-27 |
4 |
S |
$167.87 |
$71,345 |
D/D |
(425) |
1,734 |
|
- |
|
| Cozadd Bruce C |
Chairman and CEO |
• • – |
2015-08-11 |
4 |
AS |
$177.82 |
$444,550 |
D/D |
(2,500) |
296,855 |
|
- |
|
| Cox Russell J. |
EVP & Chief Commercial Officer |
• – – |
2015-08-11 |
4 |
AS |
$177.82 |
$88,910 |
D/D |
(500) |
58,602 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP and General Counsel |
• – – |
2015-08-11 |
4 |
AS |
$177.82 |
$711,280 |
D/D |
(4,000) |
37,855 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2015-08-11 |
4 |
S |
$177.71 |
$116,293 |
D/D |
(654) |
5,384 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2015-08-11 |
4 |
S |
$177.51 |
$236,494 |
D/D |
(1,330) |
11,401 |
|
- |
|
| Cozadd Bruce C |
Chairman and CEO |
• • – |
2015-08-10 |
4 |
D |
$181.48 |
$1,405,200 |
D/D |
(7,743) |
299,355 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2015-08-10 |
4 |
S |
$179.98 |
$144,180 |
D/D |
(801) |
6,038 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2015-08-10 |
4 |
D |
$181.48 |
$354,975 |
D/D |
(1,956) |
23,686 |
|
- |
|
881 Records found
|
|
Page 28 of 36 |
|
|
0.37 (0.34%) 
